share_log
Reuters ·  May 21 00:01
J&J: In Results Versus Ustekinumab Both Doses of Tremfya Showed Statistically Significant Differences on All Prespecified Pooled Endoscopic Endpoints
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment